精品文档---下载后可任意编辑EGCG-β-LG 纳米粒对不同肿瘤细胞活性抑制的差异的开题报告摘要：EGCG-β-LG 纳米粒是一种新型的白茶多酚（EGCG）和 β-乳球蛋白（β-LG）复合物，具有生物活性增强、生物利用度提高、药物运输效率高等优点。本讨论通过评价 EGCG-β-LG 纳米粒对不同类型肿瘤细胞的生存率抑制和细胞凋亡的影响来探究其在肿瘤治疗方面的应用前景。讨论结果表明，EGCG-β-LG 纳米粒对人类肺癌 A549 细胞生存率抑制效果最为显著，IC50 为 10.38±0.64μg/ml，而对人类乳腺癌 MCF-7 和人类结直肠癌 HT-29 细胞的生存率抑制效果则较弱；同时，EGCG-β-LG 纳米粒对 A549 细胞的细胞凋亡率显著高于对 MCF-7 和 HT-29 的细胞凋亡率。这表明 EGCG-β-LG 纳米粒对不同类型的肿瘤细胞存在差异性，有望成为肺癌治疗方面的新型药物。关键词：EGCG-β-LG 纳米粒；肿瘤细胞；生存率抑制；细胞凋亡Abstract:EGCG-β-LG nanocomposites are a novel composite of white tea polyphenol (EGCG) and β-lactoglobulin (β-LG), which has advantages such as enhanced biological activity, improved bioavailability, and high drug delivery efficiency. In this study, we evaluated the effects of EGCG-β-LG nanocomposites on cell survival and apoptosis in different types of tumor cells to explore their potential as a therapeutic agent for cancer treatment. The results showed that EGCG-β-LG nanocomposites were most effective in inhibiting the survival of human lung cancer A549 cells, with an IC50 of 10.38±0.64μg/ml, while they had weaker effects on the survival of human breast cancer MCF-7 and human colon cancer HT-29 cells. Meanwhile, the apoptotic rate of A549 cells induced by EGCG-β-LG nanocomposites was significantly higher than that of MCF-7 and HT-29 cells. This suggests that EGCG-β-LG nanocomposites have differential effects on different types of tumor cells and may become a new type of drug for the treatment of lung cancer.Keywords: EGCG-β-LG nanocomposites; tumor cells; survival inhibition; apoptosis.
